Is it safe?
Can LGND take a bad year?
Ligand Pharmaceuticals Incorporated holds $231M more cash than debt, so a bad year is a question about profits, not about lenders.
$231M
Net cash
- Net debt / EBITDA
- net cash
Net debt / EBITDA · no net borrowings to measure against earnings
- Altman Z-score
- 7.96
Altman Z-score · safe zone, above 3
- Interest cover
- 15.3×
Interest cover · operating profit covers the interest bill several times over
Details›
- Total debtQ2 2026
- $1.13B
- Cash and short-term investments
- $1.36B
- Net cash
- $231M
- EBITDA, trailing twelve months
- $128M
- Operating profit, trailing twelve months
- $95M
- Debt / equity
- 1.16×
- Total debt / EBITDA
- 8.83×
- Annualised volatilitytwo years of daily moves
- 38%
- Worst drawdown on file
- −77%
- Below its 52-week high
- −9.0%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.